A

Aventiv Research | Phoenix-Mesa, AZ

Research site

(Unclaimed)

Location

612 W Baseline Road, Mesa, Arizona, United States of America

Site insights

Top conditions

Top treatments

Bardoxolone Methyl

Obinutuzumab

LY3502970

KBP-5074

Orforglipron

Empagliflozin

Parent organization

This site is a part of Aventiv Research

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 7 total trials

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy (MAJESTY)

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants w...

Active, not recruiting

Primary Membranous Nephropathy

Drug: Tacrolimus

Drug: Methylprednisolone

Locations recently updated

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling

Chronic Kidney Disease

Inflammation

Drug: Placebo (Ziltivekimab B)

Drug: Placebo (Ziltivekimab C)